Understanding the genetic factors in a rare type of kidney cancer
Official title: Resolving phenotypic overlap in renal carcinoma subtypes using multi-tiered network methods
Funded at Dana-Farber Cancer Inst · NIH-11033442 · Data updated 2026-11-12
This study is looking at a rare type of kidney cancer called Translocation Renal Cell Carcinoma (tRCC) to find out how certain genes affect its growth, which could help doctors make better diagnoses and create more effective treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 7, 2025 |
| Project end | April 30, 2030 |
| Funding year | 2025 |
| Award (this year) | $172,193 |
| NIH project number | 1K25CA297149-01 |
| Project ID | NIH-11033442 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Translocation Renal Cell Carcinoma or those exhibiting symptoms consistent with this rare cancer.
✕Less likely to help
Patients with other types of kidney cancer that do not involve the specific genetic factors associated with tRCC may not benefit from this research.
What this research studies
This research focuses on Translocation Renal Cell Carcinoma (tRCC), a rare and aggressive kidney cancer that is often misdiagnosed due to its overlapping characteristics with other cancer subtypes. The study aims to identify specific gene regulatory elements and transcription factors that contribute to the progression of tRCC. By developing a novel optimization method, researchers will analyze gene expression data to better understand the activity of these factors, even with small sample sizes. This approach could lead to more accurate diagnoses and targeted therapies for patients with tRCC.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic accuracy and more effective treatment options for patients with Translocation Renal Cell Carcinoma.
How similar studies have gone: Previous research has shown promise in identifying genetic factors in other cancer types, suggesting that this approach could yield valuable insights for tRCC as well.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Ben Guebila, Marouen — Dana-Farber Cancer Inst
- Study coordinator: Ben Guebila, Marouen
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Glutamine and macrophage behavior in liver cancer
A funded project at a medical university aims to understand how the liver’s immune cells interact with a specific type of liver cancer by looking at metabolism, especially glutamine and ammonia.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Understanding how bladder cancer starts in Veterans exposed to carcinogens and the role of PPAR-g in early bladder cancer
A research team is studying how bladder cancer begins and progresses in Veterans exposed to carcinogens, focusing on the PPAR-γ protein and early precancerous changes.
-
Adding PSMA PET/CT imaging to liver cancer care for veterans
This project tests a new PET imaging approach to help diagnose and guide treatment for liver cancer in veterans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.